Reviewing the Recommendations of the Pharmaceutical and Life Sciences Sector Task Force

July 27, 2026 – On Friday July 24, the Government of Canada’s Pharmaceutical and Life Sciences Sector Task Force released its report on how Canada can strengthen the competitiveness and long-term sustainability of its pharmaceutical and life sciences sector, improve reliable and sustainable access to medicines and support economic growth.

Launched on March 18, 2026, the Task Force was created during a time of intense uncertainty and disruption in the global life sciences policy ecosystem. The implementation of Most-Favoured Nation (MFN) drug pricing policies in the United States introduced a new level of global interdependence into pricing decisions, which in turn further exacerbated a set of longstanding domestic challenges, from reduced clinical trial competitiveness, to declining investment attractiveness, to persistent delays in patient access to new therapies.

Charged with reporting jointly to the Ministers of Health and Industry, the Task Force spent four months identifying a wide array “Made-in-Canada” solutions to these challenges, drawing on a membership that encompassed a wide range of industry executives plus senior leaders from CDA-AMC, INESSS and the broader life sciences ecosystem.

As an advisory body to the Government of Canada, the Task Force itself has no formal authority or budget. What it does have, however, is the significant legitimacy accorded to a collective specifically convened by Ottawa to provide advice on how best to respond to the myriad of challenges impacting Canada’s world-class life sciences sector.

Report Highlights

While the emergence of MFN was the catalyst for the creation of the Task Force, the final report outlines a much more expansive and inclusive set of five specific challenges facing the sector:

• Canada’s pharmaceutical policies focused on cost containment and its complex and lengthy regulatory path to reimbursement have caused a progressive erosion of domestic and foreign direct investment from both innovative and generic pharmaceutical industry that is being exacerbated by global trade dynamics and pricing policy rebalancing, which may impact the launch of new medicine and future investment.

• Canada’s clinical trial environment is underperforming due to structural barriers, complex regulatory path, fragmented investment and weak data infrastructure, and drug reimbursement policies.

• Canada lacks a sovereign, connected, and accessible health and life sciences data ecosystem to fully leverage AI and enable measurement of value/outcomes and healthcare savings from life sciences innovations.

• Fragmentation across funding programs and translational infrastructure, combined with a lack of industry-academic coordination create a sub-optimal path for the translation of life sciences discoveries into venture-backed companies.

• The shortage of domestic sources of late-stage growth capital is a major structural impediment to Canada’s ability to retain Canadian ownership of venture capital-backed innovative life sciences companies and scale them into commercial stage anchor companies.

The report then lays out 39 recommendations across eight priority buckets outlined and unpacked below:

1. Regulatory Modernization – Health Canada (Recommendations 1–7): Outlining actions through which Health Canada can accelerate market authorization through a reliance framework that leverages trusted foreign regulators, rolling reviews, a single-window navigator, and lighter handling of low-risk changes.
2. Assessment of Value, Pricing, and Reimbursement (Recommendations 8–11): Reviewing and improving how drug value is assessed and how to optimize the role of CDA-AMC, the pCPA and the PMPRB.
3. Clinical Trials Environment and Competitiveness (Recommendations 12–17): Protecting the 30-day trial-application standard and builds national ethics review, contracting, infrastructure, and tax incentives to reverse Canada’s eroding share of the global clinical trial market.
4. Data Infrastructure and AI (Recommendations 18–21): Building a sovereign, pan-Canadian health data system that incorporates real-world evidence and AI capacity.
5. Strengthen Translational Research (Recommendations 22–27): Improving and accelerating the process from discovery to commercialization through improved federal coordination, stronger incubation “biohubs,” and better investment incentives.
6. Scaling Canadian-Based Life Sciences Anchor Companies (Recommendations 28–32): Mobilizing late-stage domestic capital and a clear industrial strategy (plus a wide range of existing and new funding mechanisms) to grow and retain Canadian “anchor” firms.
7. Health Sovereignty and Industrial Strategy (Recommendations 33–38): Mapping domestic assets, prioritizing strategic niches, strengthening procurement processes and diversifying domestic supply chains.
8. System Integration, Governance, and Implementation (Recommendation 39): Creating four dedicated public-private implementation teams under a single oversight body.

Santis Insights

1. The report is remarkably candid about the connection between accelerated market access policies and a compelling Canadian investment environment. Early in its Problem Statement section, the report argues that “Canada is losing ground as a competitive destination for investment and innovation, global pharmaceutical companies are increasingly deprioritizing Canada for product launches, foreign direct investment in clinical trials and manufacturing in favor of other markets with more predictable policies, faster access, and stronger recognition of innovation value.” In comprehensively reflecting long-standing industry, patient and ecosystem frustrations, this language reflects a Task Force sincerely committed to better understanding Canada’s true global position.
2. At the same time, its recommendations extend far beyond the specific market access challenges to encompass the broader Canadian life sciences ecosystem. Across its 39 recommendations, the report covers regulatory modernization, the need to increase the competitiveness of clinical trials, the opportunities presented by AI and translational research, and the imperative of scaling and growing Canada-based life sciences “anchor” companies. Only 4 of the 39 recommendations specifically address the “Assessment of value, pricing and reimbursement” – the section dealing most explicitly with expediting patient access.
3. Although the Task Force naturally prioritizes areas of federal leadership, many of its key market access recommendations target CDA-AMC and the pCPA – both organizations defined by provincial leadership. Calling on CDA-AMC to develop a “multi-dimensional value framework” is an intriguing concept, as is urging the pCPA to “consider the full value of innovation,” to review its “current consensus-based approach” and to improve the timeliness of its post-LOI listing agreements “such as within 30 to 60 days”. Despite the real and important frustrations captured by these recommendations, it’s unclear how much the federal government itself could do to ensure their implementation.
4. The Recommendations are impressive in their breadth – but disappointing in their lack of specificity. The Report argues that CDA-AMC should not only “evolve its Health Technology Assessment evaluation framework” but also “evolve its economic assessment methodology”. However, it fails to offer any details on the optimal direction, approach, speed and ultimate destination of that evolution. It calls for the need to “enhance coordination across jurisdictions” in the context of clinical trials, but is silent on what carrots and sticks Ottawa should use to drive that enhancement. It argues for the need to “Establish a product policy framework which creates market certainty for medicines that have investments in Canada” but neglects to explain what exactly this framework would do, how it would work, what levers it would pull and how its success would be measured. Furthermore, many of the recommendations with the most detail refer to initiatives already underway, such as urging CDA-AMC to “continue its efforts to ensure its reviews are conducted in a stacked/concurrent manner with Health Canada and with pCPA negotiation pathways. “
5. The report avoids any reference to specific funding to achieve specific goals – even as it calls for some very aggressive timelines. The report doesn’t suggest any allocation – or reallocation – of federal investment, nor does it prioritize or sequence the recommendations themselves. Instead, this work will presumably fall to the 4 “Implementation Teams” it also proposes:
   1. A Regulatory Modernization, Pricing and Reimbursement Team
   2. A Clinical Trials, Data Infrastructure/AI and Translational Research Team
   3. A Canadian-Based Life Sciences Anchor Company Scaling Team; and
   4. A Health Sovereignty & Industrial Strategy team

The Task Force is calling on these four teams to help prioritize all recommendations regarding Health Canada, CDA-AMC, the pCPA and the PMPRB within 3 months; and all recommendations regarding clinical trials, data and AI, translational research, scaling Canadian-based life sciences anchor companies and health sovereignty within 9 months. These are extremely ambitious timelines, and ones the federal government may be very challenged to accept.

Final Thoughts

The report is best read as a foundation to build on – not a clear pathway to follow. It does an exceptional job of illuminating the multiple challenges threatening a strategically significant sector, and proposes dozens of potential recommendations to address them. However, its recommendations are largely broad and sweeping, which in turn leaves a huge amount of room for interested voices to fill in the blanks by making their case for prioritization and sequencing, funding requirements and implementation considerations.

The onus is now on Health Canada and ISED to respond to the report and the expectations it has generated. That response will be compounded by multiple factors, including ongoing CUSMA negotiations and an increasingly acrimonious trade relationship with the U.S.; broader federal-provincial-territorial dynamics – including the Premiers’ call for sustained annual growth rate in the Canada Health Transfer at last week’s Council of the Federation meeting – and HERC’s ongoing work to support and strengthen the commercialization ecosystem surrounding Canadian start-ups and SMEs.

With a Fall federal budget just around the corner, interest-holders now have a perfect opportunity to leverage the pre-budget consultation window to add their own details to the broad solution contours outlined by the Task Force – and in so doing help to turn a promising but imprecise document into a detailed plan of action positioned to drive meaningful change.